State Key Laboratory of Component-based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China; Engineering Research Center of Modern Chinese Medicine Discovery and Preparation Technique, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China.
State Key Laboratory of Component-based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China; Engineering Research Center of Modern Chinese Medicine Discovery and Preparation Technique, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China.
Biomed Pharmacother. 2021 Jan;133:111072. doi: 10.1016/j.biopha.2020.111072. Epub 2020 Dec 8.
Idiopathic pulmonary fibrosis (IPF) is a progressive pulmonary interstitial inflammatory disease of unknown etiology, and is also a sequela in severe patients with the Coronavirus Disease 2019 (COVID-19). Nintedanib and pirfenidone are the only two known drugs which are conditionally recommended for the treatment of IPF by the FDA. However, these drugs pose some adverse side effects such as nausea and diarrhoea during clinical applications. Therefore, it is of great value and significance to identify effective and safe therapeutic drugs to solve the clinical problems associated with intake of western medicine. As a unique medical treatment, Traditional Chinese Medicine (TCM) has gradually exerted its advantages in the treatment of IPF worldwide through a multi-level and multi-target approach. Further, to overcome the current clinical problems of oral and injectable intakes of TCM, pulmonary drug delivery system (PDDS) could be designed to reduce the systemic metabolism and adverse reactions of the drug and to improve the bioavailability of drugs. Through PubMed, Google Scholar, Web of Science, and CNKI, we retrieved articles published in related fields in recent years, and this paper has summarized twenty-seven Chinese compound prescriptions, ten single TCM, and ten active ingredients for effective prevention and treatment of IPF. We also introduce three kinds of inhaling PDDS, which supports further research of TCM combined with PDDS to treat IPF.
特发性肺纤维化（IPF）是一种病因不明的进行性肺间质炎症性疾病，也是严重 2019 冠状病毒病（COVID-19）患者的后遗症。尼达尼布和吡非尼酮是美国食品和药物管理局（FDA）唯一有条件推荐用于治疗 IPF 的两种已知药物。然而，这些药物在临床应用中会引起一些不良反应，如恶心和腹泻。因此，寻找有效且安全的治疗药物来解决与西药摄入相关的临床问题具有重要价值和意义。作为一种独特的医疗方法，中药（TCM）通过多层次、多靶点的方法，在全球范围内逐渐发挥其在 IPF 治疗方面的优势。此外，为了克服中药口服和注射的当前临床问题，可以设计肺部药物递送系统（PDDS），以减少药物的全身代谢和不良反应，并提高药物的生物利用度。通过 PubMed、Google Scholar、Web of Science 和中国知网（CNKI），我们检索了近年来相关领域发表的文章，本文总结了 27 种复方中药处方、10 种单味中药和 10 种有效防治 IPF 的活性成分。我们还介绍了三种吸入性 PDDS，为进一步研究 TCM 联合 PDDS 治疗 IPF 提供了支持。
